Physician profile
David Dodson
NPI 1619943834
$1,559.02
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $161 · 2022: $89.40 · 2024: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $241.76 | 2019-2020 | |
| Pfizer INC. | $210.84 | 2019-2020 | |
| Amgen INC. | $197.15 | 2019-2022 | |
| Edwards Lifesciences Corporation | $178.50 | 2024 | Sapien 3 Ultra Resilia |
| Silk Road Medical, INC. | $163.69 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abbvie INC. | $146.86 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $124.98 | 2024 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $70.49 | 2019 | |
| Amarin Pharma, INC. | $61.99 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.78 | 2019 | |
| Allergan, INC. | $25.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $23.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.